Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Capsazepine for TRPV1 Ion Channel Antagonism
2026-08-31
Capsazepine provides a practical pharmacological switch for separating TRPV1-driven nociception from broader neuronal and cancer-cell responses. This workflow-focused guide covers assay setup, concentration selection, calcium imaging, pain-model interpretation, apoptosis studies, and troubleshooting of solubility and off-target effects.
-
PRMT5, Splicing, and Metabolism in MYCN Neuroblastoma
2026-08-31
The reference study identifies a mechanistic link between PRMT5-dependent spliceosomal control, epitranscriptomic regulation, and glutamine metabolism in MYCN-amplified neuroblastoma. Its integrated pharmacological, transcriptomic, isotope-tracing, molecular, and mouse-model analyses show that altered RNA processing can reduce GLS protein abundance and expose a metabolic vulnerability relevant to cancer metabolism research.
-
7ACC2: Monocarboxylate Transporter 1 Inhibitor
2026-08-30
7ACC2 is a carboxycoumarin monocarboxylate transporter 1 inhibitor that blocks MCT1-associated lactate uptake at a reported IC50 of approximately 10 nM in SiHa cells. Its reported effects on mitochondrial pyruvate transport and tumor radiosensitization make it a useful research probe for cancer metabolism research, but the available evidence does not establish clinical efficacy.
-
Lypressin Acetate: Workflows for GPCR Research
2026-08-29
Lypressin acetate is a lysine-containing vasopressin analog for connecting V1a, V1b, and V2 receptor biology with antidiuretic, vasopressor, and emerging antiviral assays. This workflow-centered guide covers assay setup, quantitative activity interpretation, stability controls, and the limitations of extending receptor pharmacology into SARS-CoV-2 RdRp research.
-
PR-619 for DUB Pathway Assays
2026-08-28
PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for separating DUB-driven protein accumulation from direct proteasome blockade. This workflow-focused guide covers dose design, autophagy and ubiquitination assays, cancer biology research, neurodegenerative disease models, and practical troubleshooting.
-
CB-839 and the Splicing–Glutamine Axis in Neuroblastoma
2026-08-28
PRMT5-dependent splicing can expose a glutamine-metabolic weakness in MYCN-amplified neuroblastoma. This article explains how CB-839 (Telaglenastat), a selective GLS1 inhibitor, can serve as a pharmacologic probe for testing that vulnerability while improving translational study design.
-
Viral RIPK3 Degradation and Inflammation
2026-08-27
Liu et al. identified a family of orthopoxvirus proteins, termed viral inducers of RIPK3 degradation, that use host SCF machinery to promote RIPK3 ubiquitination and proteasomal loss. The study connects this immune-evasion mechanism to necroptosis suppression, viral replication, inflammation, and disease severity in mouse infection models.
-
BACE Inhibition, Aβ, and Synaptic Transmission
2026-08-27
Satir et al. tested whether partial β-secretase inhibition could reduce amyloid beta secretion without disrupting neuronal function. Using primary rat cortical cultures and optical electrophysiology, they found that Aβ reduction below 50% did not impair synaptic transmission, whereas stronger inhibition reduced both Aβ secretion and synaptic activity.
-
BCA Protein Assay Kit for Colitis Research
2026-08-26
Discover how the BCA Protein Assay Kit supports rigorous bicinchoninic acid protein quantification in DSS-colitis research. This guide connects matrix-aware protein concentration measurement with barrier biology, immunoassays, and microbiome–metabolome interpretation.
-
Molidustat (BAY85-3934) in Cell Assays
2026-08-26
A scenario-based guide to using Molidustat (BAY85-3934), SKU B5861, in hypoxia, viability, proliferation, and cytotoxicity workflows. It connects HIF-PH biology with formulation control, assay interpretation, and practical product-selection decisions.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-08-25
A 2026 FASEB Journal study developed chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. The approach restored nuclear p21, altered cell-cycle and DNA-damage markers, and suppressed orthotopic tumor growth while producing strong bladder-localized expression with limited systemic distribution in mice.
-
Mestranol and Reversible Lysosomal Stress in Microglia
2026-08-25
A 2026 Aquatic Toxicology study identifies mestranol as an inducer of a reversible lysosomal storage–like state in zebrafish microglia. The work separates preserved phagocytic uptake from impaired intracellular digestion and provides a live model for studying environmental estrogen–associated neuroimmunotoxicity.
-
Firefly Luciferase mRNA as a Delivery Benchmark
2026-08-24
Firefly Luciferase mRNA can do more than report gene expression: it can reveal how capping, nucleotide modification, poly(A) architecture, and delivery determine functional protein output. This article connects assay design with mechanistic lessons from emerging non-LNP mRNA delivery research.
-
CAMLs in Blood: Phenotypes and Clinical Utility
2026-08-24
The reference study presents circulating cancer-associated macrophage-like cells (CAMLs) as phagocytic polyploid giant cancer cells with measurable links to progression and disease spread across multiple solid tumors. Its prospective, multi-institutional design and biological phenotyping suggest that CAMLs may provide a blood-based window into metastatic niche formation, although their prognostic and mechanistic roles require further validation.
-
Pollen Interference in Hazardous Aerosol Detection
2026-08-23
The reference study shows that pollen can distort excitation–emission matrix fluorescence classification of hazardous bioaerosols, but feature transformation can substantially reduce this interference. Combining preprocessing, fast Fourier transform analysis, and random forest classification produced 89.24% accuracy across 31 sample types and separated several important bacterial and toxin signals.